<DOC>
	<DOCNO>NCT01600573</DOCNO>
	<brief_summary>This clinical trial shall clarify efficacy safety pazopanib combination weekly topotecan patient platinum-resistant intermediate platinum-sensitive recurrent epithelial ovarian cancer , fallopian peritoneal carcinoma</brief_summary>
	<brief_title>Pazopanib Weekly Topotecan Patients Recurrent Ovarian Cancer ( TOPAZ )</brief_title>
	<detailed_description>This study prospective single-arm , open-label , multicenter phase I/II trial . The phase I-trial dose-escalation trial determine maximum tolerate dose ( MTD ) pazopanib combination weekly topotecan . The phase II-trial single arm open-label trial ass safety efficacy combination treatment .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>write informed consent histologically confirm diagnosis epithelial ovarian cancer , primary peritoneal carcinoma fallopian tube cancer platinum resistant ( recurrence within 6 month platinumcontaining regimen ) platinum refractory ( progression platinum treatment ) intermediate platinumsensitive ( recurrence within 12 month platinumbased primary therapy ) disease 2 prior treatment regimens epithelial ovarian cancer Age 18 year ECOG 0 1 adequate organ function measurable disease evaluable disease accord RECIST criterion able swallow retain oral medication life expectancy least 12 week nonchildbearing potential negative serum pregnancy test woman childbearing potential agrees use adequate contraception 14 day exposure investigational product , dose period , least 6 month last dose investigational product . Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . prior malignancy ; subject another malignancy diseasefree 5 year effect progression free survival , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . Screening CNS image study ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) require clinically indicated subject history CNS metastases . clinically significant gastrointestinal abnormality might interfere oral dosing may increase risk gastrointestinal bleeding clinically significant gastrointestinal abnormality may affect absorption investigational product Grade 3 4 diarrhoea Any unstable serious concurrent condition ( e.g. , active infection require systemic therapy ) poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg ] Prolongation correct QT interval ( QTc ) &gt; 450 millisecond use Bazett 's formula History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting ; myocardial infarction ; unstable angina ; symptomatic peripheral vascular disease ; coronary artery bypass graft surgery Class III IV congestive heart failure define New York Heart Association ( NYHA ) History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month Macroscopic hematuria Hemoptysis excess 2.5 mL ( one half teaspoon ) within 8 week first dose study drug Evidence active bleeding bleed diathesis know endobronchial lesion and/or lesion infiltrate major pulmonary vessel and/or involvement large pulmonary vessel tumor prior major surgery trauma within 14 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer Chemotherapy radiation therapy tumour embolization within 2 week prior first dose study drug biological therapy , immunotherapy , hormonal therapy treatment investigational agent within 14 day ( bevacizumab , 60 day ) 5 halflives , whichever long prior first dose study drug unable unwilling discontinue predefined prohibited medication list protocol ( refer section 4.2.3 ) 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib psychological , familial , sociological , geographical condition permit compliance protocol clinically assessed inadequate venous access PK sample condition unstable could jeopardize safety patient compliance study legal incapacity limited legal capacity Participation another clinical study experimental therapy within 30 day start treatment Subjects house institution official legal order Pregnancy lactation period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ovarian cancer</keyword>
</DOC>